- Home
- TARA vs GCO Comparison
TARA vs GCO Comparison
Compare TARA & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARA | GCO |
|---|---|---|
| Founded | N/A | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 286.0M |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | TARA | GCO |
|---|---|---|
| Price | $5.11 | $28.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $21.67 | ★ $33.00 |
| AVG Volume (30 Days) | ★ 673.0K | 206.9K |
| Earning Date | 05-07-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.25 | ★ 171.84 |
| EPS | N/A | ★ 1.25 |
| Revenue | $2,948,000.00 | ★ $2,606,898,000.00 |
| Revenue This Year | N/A | $0.78 |
| Revenue Next Year | N/A | $2.12 |
| P/E Ratio | ★ N/A | $22.75 |
| Revenue Growth | N/A | ★ 13.71 |
| 52 Week Low | $2.77 | $16.19 |
| 52 Week High | $7.82 | $38.95 |
Technical Indicators
Market Signals| Indicator | TARA | GCO |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 56.27 |
| Support Level | $4.95 | $27.02 |
| Resistance Level | $5.39 | $29.79 |
| Average True Range (ATR) | 0.29 | 1.34 |
| MACD | 0.01 | 0.40 |
| Stochastic Oscillator | 44.93 | 76.73 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About GCO Genesco Inc.
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.